Nyxoah (NYXH)
(Delayed Data from NSDQ)
$9.25 USD
+0.03 (0.27%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $9.22 -0.03 (-0.32%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NYXH 9.25 +0.03(0.27%)
Will NYXH be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NYXH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NYXH
Nyxoah SA (NYXH) Reports Q2 Loss, Misses Revenue Estimates
Clover Health Investments, Corp. (CLOV) Q2 Earnings and Revenues Beat Estimates
NYXH: What are Zacks experts saying now?
Zacks Private Portfolio Services
CareCloud, Inc. (CCLD) Reports Q1 Loss, Misses Revenue Estimates
Privia Health (PRVA) Misses Q1 Earnings and Revenue Estimates
Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates
Other News for NYXH
Stifel Nicolaus Reaffirms Their Buy Rating on Nyxoah (NYXH)
Buy Rating Reiterated for Nyxoah Amid Promising Genio System Performance and Significant Market Opportunity
DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Nyxoah Breaks Above 200-Day Moving Average - Bullish for NYXH
Nyxoah’s Genio Shows Promise for OSA Management